

**Title:**

**Persistence of Signs and Symptoms in Treated Patients with IgAN: Evidence from Real-World Data**

**Authors: R. Lafayette<sup>1</sup>; M. Kroes<sup>2</sup>; C. Aldworth<sup>2</sup>; L. Prieto Rodriguez<sup>2</sup>; AT. George<sup>3</sup>; W. Wang<sup>4</sup>; J. de Courcy<sup>5</sup>; K. Golden<sup>5</sup>; E. Chatterton<sup>5</sup>; L. Yao<sup>6</sup>; D. Roccatello<sup>7</sup>**

<sup>1</sup>Stanford University Medical Center, United States; <sup>2</sup>Novartis Pharma AG, Basel, Switzerland, <sup>3</sup>Novartis Healthcare Private Limited, Hyderabad, India; <sup>4</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; <sup>5</sup>Adelphi Real World, Bollington, England, United Kingdom; <sup>6</sup>The First Hospital of China Medical University, Shenyang, PR China; <sup>7</sup>University of Turin, Turin, Italy

**Background:**

Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, with an estimated annual incidence of 25 per million. It currently has limited treatment options. This analysis aimed to describe IgAN signs and symptoms (S&S) in treated patients.

**Methods:**

The Adelphi IgAN Disease Specific Programme was a point-in-time survey of IgAN-treating nephrologists in the US, EU5 (France, Germany, Italy, Spain, UK) and Asia (China and Japan) between June and October 2021. Nephrologists completed structured online records for successive patients presenting with IgAN, including patient's demographics, IgAN treatment history, and a list of 29 current IgAN S&S.

**Results:**

295 nephrologists completed records for 1376 patients treated for a minimum of one week at time of survey. Mean patient age was 42.6 years, 59% were men. Median time since treatment initiation was 86 weeks (US 61, EU5 121, Asia 76).

Despite treatment with standard of care (ACEi, ARB, Statins, Corticosteroids), most patients presented with S&S at time of survey. This was consistent in patients with a longer treatment duration. Common S&S experienced were proteinuria, hematuria, hypertension, and fatigue (**Table 1**).

A higher proportion of patients in their second year of treatment were at a better CKD stage than those in their first year of treatment, or those treated for >2 years.

Of those patients treated for more than two years, US 26%, EU5 31%, Asia 24% had >1g proteinuria/day where reported.

**Conclusion:**

Despite treatment, IgAN S&S persist in the majority of patients. Proteinuria persists in many patients increasing risk of progression to kidney failure. This shows a need for better treatment options for IgAN.

<b>Table 1</b>	<b>US</b>				<b>EU5</b>				<b>Asia</b>			
<b>Time since treatment initiation (Years)</b>	<b>Any n=232</b>	<1y n=105	1-2y n=50	>2 y n=77	<b>Any n=474</b>	<1y n=139	1-2y n=82	>2 y n=253	<b>Any n=670</b>	<1y n=258	1-2y n=125	>2 y n=287
<b>Number of signs &amp; symptoms Mean (SD)</b>	<b>2.2 (2.4)</b>	2.6 (2.4)	2.0 (2.4)	2.0 (2.5)	<b>1.8 (1.8)</b>	2.1 (1.9)	1.9 (1.6)	1.6 (1.8)	<b>2.6 (2.5)</b>	2.6 (2.4)	2.2 (2.2)	2.7 (2.7)
% Currently symptomatic	<b>78%</b>	80%	78%	75%	<b>75%</b>	80%	79%	72%	<b>79%</b>	83%	75%	76%
<b>Top 10 signs &amp; symptoms</b>												
Proteinuria	<b>45%</b>	50%	46%	38%	<b>36%</b>	41%	33%	34%	<b>54%</b>	60%	53%	49%
Hematuria	<b>30%</b>	34%	28%	26%	<b>20%</b>	24%	16%	19%	<b>30%</b>	31%	25%	31%
Hypertension	<b>27%</b>	36%	18%	21%	<b>28%</b>	32%	33%	25%	<b>22%</b>	17%	15%	28%
Fatigue	<b>22%</b>	28%	16%	18%	<b>16%</b>	19%	20%	12%	<b>22%</b>	21%	23%	24%
Edema in extremities	<b>16%</b>	17%	8%	18%	<b>9%</b>	14%	6%	8%	<b>18%</b>	22%	11%	18%
High cholesterol	<b>20%</b>	27%	10%	17%	<b>14%</b>	13%	15%	14%	<b>8%</b>	10%	5%	9%
Discolored urine	<b>7%</b>	8%	4%	8%	<b>5%</b>	5%	6%	5%	<b>17%</b>	23%	11%	13%
Sleep problems	<b>7%</b>	7%	6%	9%	<b>7%</b>	5%	10%	7%	<b>9%</b>	8%	10%	10%
Pain in abdomen	<b>4%</b>	3%	10%	1%	<b>5%</b>	6%	7%	4%	<b>11%</b>	5%	10%	17%
Oliguria	<b>1%</b>	1%	2%	0%	<b>4%</b>	7%	1%	3%	<b>9%</b>	12%	2%	8%
<b>Current GFR</b>												
GFR ≥45 mL/min/1.73 m2	<b>71%</b>	68%	76%	71%	<b>74%</b>	73%	80%	74%	<b>82%</b>	89%	91%	72%
GFR <45 mL/min/1.73 m2	<b>29%</b>	32%	24%	29%	<b>26%</b>	27%	20%	26%	<b>18%</b>	11%	9%	28%
<b>Current Proteinuria (where reported)</b>												
	n=209	n=90	n=45	n=74	n=420	n=121	n=71	n=228	n=627	n=238	n=120	n=269
>1g/day	37%	48%	36%	26%	37%	47%	41%	31%	24%	29%	16%	24%
≤1g/day	63%	52%	64%	74%	63%	53%	59%	69%	76%	71%	84%	76%